Tom Battersby

Executive Director, Biomarker-Research Gilead Sciences

Seminars

Tuesday 23rd September 2025
Biomarker-Driven Phase 3 Clinical Trial Enrollment With a Hybrid Approach of Qualified Local & Central Laboratory Developed Tests
6:00 pm
  • The ENHANCE-02 trial enrolled Acute Myeloid Leukemia subjects with TP53 mutation
  • Assay concordance was estimated for the collection of local LDTs and a planned CDx assay
  • Effects of this approach on enrollment speed and simulated trial efficacy analysis were examined
Tom Battersvy